Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients

af Fujiwara, Yutaka, Kiyota, Naomi, Chayahara, Naoko, Suzuki, Akiyuki, Umeyama, Yoshiko, Mukohara, Toru, Minami, Hironobu
Udgivet 2011

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

af Takahashi, Masato, Masuda, Norikazu, Nishimura, Reiki, Inoue, Kenichi, Ohno, Shinji, Iwata, Hiroji, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Toi, Masakazu
Udgivet i Cancer Med (2020)

Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma

af Eto, Masatoshi, Uemura, Hirotsugu, Tomita, Yoshihiko, Kanayama, Hiroomi, Shinohara, Nobuo, Kamei, Yoichi, Fujii, Yosuke, Umeyama, Yoshiko, Ozono, Seiichiro, Naito, Seiji, Akaza, Hideyuki
Udgivet i Cancer Sci (2014)

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

af Tomita, Yoshihiko, Uemura, Hirotsugu, Oya, Mototsugu, Shinohara, Nobuo, Habuchi, Tomonori, Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Rini, Brian I.
Udgivet i BMC Cancer (2019)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

af Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakuzu
Udgivet i Breast Cancer (2019)

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer

af Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakazu
Udgivet i Breast Cancer (2019)

Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III tr...

af Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji
Udgivet i Jpn J Clin Oncol (2015)

Overall survival of first‐line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study

af Oya, Mototsugu, Tomita, Yoshihiko, Fukasawa, Satoshi, Shinohara, Nobuo, Habuchi, Tomonori, Rini, Brian I., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Uemura, Hirotsugu
Udgivet i Cancer Sci (2017)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study

af Masuda, Norikazu, Nishimura, Reiki, Takahashi, Masato, Inoue, Kenichi, Ohno, Shinji, Iwata, Hiroji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Toi, Masakazu
Udgivet i Cancer Sci (2018)

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib...

af Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Ohtani, Shoichiro, Shimizu, Chikako, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakazu
Udgivet i Breast Cancer (2020)

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial

af Kudo, Masatoshi, Motomura, Kenta, Wada, Yoshiyuki, Inaba, Yoshitaka, Sakamoto, Yasunari, Kurosaki, Masayuki, Umeyama, Yoshiko, Kamei, Yoichi, Yoshimitsu, Junichiro, Fujii, Yosuke, Aizawa, Mana, Robbins, Paul B., Furuse, Junji
Udgivet i Liver Cancer (2021)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

af Tamura, Kenji, Mukai, Hirofumi, Naito, Yoichi, Yonemori, Kan, Kodaira, Makoto, Tanabe, Yuko, Yamamoto, Noboru, Osera, Shozo, Sasaki, Masaoki, Mori, Yuko, Hashigaki, Satoshi, Nagasawa, Takashi, Umeyama, Yoshiko, Yoshino, Takayuki
Udgivet i Cancer Sci (2016)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup...

af Masuda, Norikazu, Inoue, Kenichi, Nakamura, Rikiya, Rai, Yoshiaki, Mukai, Hirofumi, Ohno, Shinji, Hara, Fumikata, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Huang, Xin, Iwata, Hiroji
Udgivet i Int J Clin Oncol (2018)

Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study

af Kudo, Masatoshi, Kang, Yoon-Koo, Park, Joong-Won, Qin, Shukui, Inaba, Yoshitaka, Assenat, Eric, Umeyama, Yoshiko, Lechuga, Maria José, Valota, Olga, Fujii, Yosuke, Martini, Jean-Francois, Williams, J. Andrew, Obi, Shuntaro
Udgivet i Liver Cancer (2018)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3

af Iwata, Hiroji, Umeyama, Yoshiko, Liu, Yuan, Zhang, Zhe, Schnell, Patrick, Mori, Yuko, Fletcher, Olivia, Marshall, Jean‐Claude, Johnson, Jillian G., Wood, Linda S., Toi, Masakazu, Finn, Richard S., Turner, Nicholas C., Bartlett, Cynthia Huang, Cristofanilli, Massimo
Udgivet i Oncologist (2021)

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup a...

af Mukai, Hirofumi, Shimizu, Chikako, Masuda, Norikazu, Ohtani, Shoichiro, Ohno, Shinji, Takahashi, Masato, Yamamoto, Yutaka, Nishimura, Reiki, Sato, Nobuaki, Ohsumi, Shozo, Iwata, Hiroji, Mori, Yuko, Hashigaki, Satoshi, Muramatsu, Yasuaki, Nagasawa, Takashi, Umeyama, Yoshiko, Lu, Dongrui R., Toi, Masakazu
Udgivet i Int J Clin Oncol (2018)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101

af Uemura, Motohide, Tomita, Yoshihiko, Miyake, Hideaki, Hatakeyama, Shingo, Kanayama, Hiro‐omi, Numakura, Kazuyuki, Takagi, Toshio, Kato, Tomoyuki, Eto, Masatoshi, Obara, Wataru, Uemura, Hirotsugu, Choueiri, Toni K., Motzer, Robert J., Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, di Pietro, Alessandra, Oya, Mototsugu
Udgivet i Cancer Sci (2020)